Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymorphone ER open-label extension for cancer or back pain
NCT00904280Phase 3Completed
- Sponsor
- Endo International plc
- Start
- Mar 2001
- Primary completion
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxymorphone in cancer pain and low back pain (LBP), sponsored by Endo International plc. Primary endpoints: Brief Pain Inventory (BPI) Pain Intensity at 1 year, Recall of Average Pain Relief at 1 year and 2 more. Started Mar 2001; status: completed.
02
Drugs
oxymorphone
03
Conditions
cancer painlow back pain (LBP)
Beyond the preview
Go deeper on NCT00904280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00904280.